MedTrace Logo

Cost-effectiveness Study of Epoetin Alfa and Darbepoetin Alfa in Adult Patients With Cancer Who Have Anemia

NCT00264108 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 492

Last updated 2014-05-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the cost-effectiveness of epoetin alfa compared with darbepoetin alfa in the treatment of anemia in adults receiving chemotherapy for cancer. Epoetin alfa and darbepoetin alfa are genetically engineered proteins that stimulate red blood cell production.

Conditions

Interventions

DRUG

Darbepoetin alfa

Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.

DRUG

Epoetin alfa

40,000 IU once weekly, variable treatment length.

Sponsors & Collaborators

  • Janssen-Cilag B.V.

    lead INDUSTRY

Principal Investigators

  • Janssen-Cilag B.V. Clinical Trial · Janssen-Cilag B.V.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-06-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00264108 on ClinicalTrials.gov